Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  NMCD. Nutrition Metabolism and Cardiovascular Diseases

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.numecd.2009.03.021PMID 19427768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

  2010cited by this paper
• Similarity of the Impact of Type 1 and Type 2 Diabetes on Cardiovascular Mortality in Middle-Aged Subjects

  2010cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Multimorbidity due to diabetes mellitus and chronic kidney disease and outcomes in chronic heart failure.

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009influential reference
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Glucometrics in Patients Hospitalized With Acute Myocardial Infarction: Defining the Optimal Outcomes-Based Measure of Risk

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?

  2008cited by this paper
• Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.

  2008cited by this paper
• Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

  2008influential reference
• Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

  2008cited by this paper
• Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)

  2007cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007influential reference
• Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

  2007cited by this paper
• Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs

  2006influential reference
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

  2006influential reference
• Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.

  2006cited by this paper
• Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

  2005influential reference
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association: response to Nesto.

  2004cited by this paper
• Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Decreased insulin requirement in relation to GFR in nephropathic Type 1 and insulin‐treated Type 2 diabetic patients

  2003cited by this paper
• Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

  2002cited by this paper
• Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.

  2000cited by this paper
• The QUORUM statement.

  2000cited by this paper
• Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction

  1999cited by this paper
• Bias in meta›analysis detected by a simple, graphical test

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Meta-analysis: Principles and procedures

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• [Insulin therapy in type II diabetes].

  1997cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Operating characteristics of a rank correlation test for publication bias.

  1994cited by this paper
• Insulin Therapy in Type II Diabetes

  1993cited by this paper
• The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy.

  1975cited by this paper

• Electrocardiographic Changes of Sinoatrial Dysfunction in Hypoglycemia: A Case Report

  2025cites this paper
• Glycemic Control in Patients with Employer-Sponsored Health Benefits

  2025cites this paper
• The involvement of specialists in primary healthcare teams for managing diabetes: a systematic review and meta-analysis

  2025cites this paper
• Metabolic risk factor targets in relation to clinical characteristics and comorbidities among individuals with type 2 diabetes treated in primary care – The countrywide cross‐sectional AUSTRO‐PROFIT study

  2024cites this paper
• Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study

  2024cites this paper
• Effect of a Dietary Intervention on Insulin Requirements and Glycemic Control in Type 1 Diabetes: A 12-Week Randomized Clinical Trial

  2024cites this paper
• Risk of Cardiovascular Events in Adults Aged 40 to 79 Years with Diagnosed Hypertension, High Cholesterol, and/or Diabetes but Not on Medications: Findings from Nationwide Cross-Sectional Studies

  2024cites this paper
• Effectiveness of Dietitian-Involved Lifestyle Interventions in Diabetes Management Among Arab Populations: A Systematic Review and Meta-Analysis

  2024cites this paper
• Exploring the underlying mechanisms linking adiposity and cardiovascular disease: A prospective cohort study of 404,332 UK Biobank participants.

  2023cites this paper
• SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS

  2023cites this paper
• Treatment of type 2 diabetes patients with heart conditions

  2023cites this paper
• Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System

  2023cites this paper
• The association between trajectories of risk factors and risk of cardiovascular disease or mortality among patients with diabetes or hypertension: A systematic review

  2022cites this paper
• Diabetes mellitus, hypertension, and HbA1c, as risk factors for arterial stiffness

  2022cites this paper
• Italian guidelines for the treatment of type 2 diabetes

  2022cites this paper
• Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

  2022cites this paper
• Italian guidelines for the treatment of type 2 diabetes.

  2022cites this paper
• Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events

  2022cites this paper
• Pre-diabetes, Diabetes, Hyperglycemia, and Stroke: Bittersweet Therapeutic Opportunities

  2022cites this paper
• Diabetes mellitus is associated with a higher relative risk for venous thromboembolism in females than in males.

  2022cites this paper
• Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network metanalysis of randomized, active comparator-controlled trials.

  2021cites this paper
• SGLT-2 inibitori alla luce delle nuove linee guida italiane per il trattamento del diabete di tipo 2: un trattamento-costo efficace?

  2021cites this paper
• Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients with Type 2 Diabetes Mellitus.

  2021cites this paper
• Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials

  2021cites this paper
• Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.

  2021cites this paper
• Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.

  2021cites this paper
• Glycemic Control Status and Long-Term Clinical Outcomes in Diabetic Chronic Total Occlusion Patients: An Observational Study

  2021cites this paper
• Lifestyle Interventions to Improve Glycemic Control in Adults with Type 2 Diabetes Living in Low-and-Middle Income Countries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs)

  2021cites this paper
• Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts

  2021cites this paper
• Diabetes and Metabolism

  2020cites this paper
• Plant-Based Diets for Type 1 Diabetes

  2020cites this paper
• Effect of vegetarian dietary patterns on cardiometabolic risk factors in diabetes: A systematic review and meta-analysis of randomized controlled trials.

  2019cites this paper
• Mechanisms for improving diabetes patient–provider communication through optimal use of e-clinical technologies

  2019cites this paper
• How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area

  2019cites this paper
• Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials

  2019cites this paper
• Insulinotherapy in diabetes melittus type 1

  2019cites this paper
• PPA_A_207008 981..992

  2019cites this paper
• Evidence discussing glycaemic targets that need to be achieved to reduce macrovascular disease risk in type 2 diabetes

  2019cites this paper
• Controversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground

  2019cites this paper
• Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes

  2019cites this paper
• Effects of sulfonylurea treatment on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus: A network meta-analysis

  2018cites this paper
• Role of Tight Glycemic Control during Acute Coronary Syndrome on CV Outcome in Type 2 Diabetes

  2018cites this paper
• Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials

  2018cites this paper
• Vegetarian Dietary Patterns and Cardiovascular Disease.

  2018cites this paper
• Cardio-Metabolic Benefits of Plant-Based Diets

  2017cites this paper
• Cardiovascular safety of insulin: Between real‐world data and reality

  2017cites this paper
• Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.

  2017cites this paper
• Risk of cardiovascular disease among diabetic patients in rural population of Central India

  2017cites this paper
• Effects of Supersession Prescription/Metformin Combination Therapy in Overweight and Obese Individuals with Type 2 Diabetes

  2017cites this paper
• Impacto cardiovascular de la hipoglicemia

  2017cites this paper
• Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes

  2017cites this paper
• Vegetarian Diets in People With Type 2 Diabetes

  2017cites this paper
• Gaps and barriers in the control of blood glucose in people with type 2 diabetes

  2017cites this paper
• Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL‐6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice

  2017cites this paper
• Effects of pioglitazone treatment on blood leptin levels in patients with type 2 diabetes

  2017cites this paper
• Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials.

  2016cites this paper
• The Combination of Canagliflozin with a Half-Dose of Glimepiride Improves Glycemic Control and Blood Glucose Perturbation without Increasing the Risk of Hypoglycemia and Ketosis

  2016cites this paper
• Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places.

  2016cites this paper
• Hyperglycemia, hypoglycemia and glycemic variability in the elderly: a fatal triad?

  2016cites this paper
• Effect modification in the relation between HbA 1 c and cardiovascular disease and mortality in patients with type 2 diabetes . Running title : Effect modification between HbA 1 c and endpoints

  2016cites this paper
• Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.

  2016cites this paper
• Guía de práctica clínica para la prevención, diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años

  2016cites this paper
• Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

  2016cites this paper
• The evolving frontier of diabetes therapy: The renaissance of glycemology.

  2016cites this paper
• Clinical practice guideline for the prevention, early detection, diagnosis, management and follow up of type 2 diabetes mellitus in adults

  2016cites this paper
• The Genetics of Coronary Heart Disease across Ethnicities and in those with Type 2 Diabetes

  2016cites this paper
• Metabolic memory and all‐cause death in community‐based patients with type 2 diabetes: the Fremantle Diabetes Study

  2016cites this paper
• Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations

  2016cites this paper
• Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials

  2016cites this paper
• Screening for Abnormal Glucose and Type 2 Diabetes Mellitus: A Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation

  2015cites this paper
• WITHDRAWN: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.

  2015cites this paper
• Glucose‐lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all‐cause mortality, cardiovascular events and cancer

  2015cites this paper
• The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

  2015cites this paper
• Новый ингибитор ДПП-4 госоглиптин: первый опыт изучения эффективности и безопасности при сахарном диабете 2 типа в России Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

  2015cites this paper
• Optimierung der glykämischen Kontrolle und des kardiovaskulären Risikos

  2015cites this paper
• Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force

  2015cites this paper
• Comparison of basal insulin therapies with regard to the risk of acute myocardial infarction in patients with type 2 diabetes: an observational cohort study

  2015cites this paper
• Independent association between glycated hemoglobin and arterial stiffness in healthy men

  2015cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?

  2015cites this paper
• Trends in the Risk for Cardiovascular Disease among Adults with Diabetes in Oman.

  2015cites this paper
• Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials

  2014cites this paper
• Effectiveness of a Training Course for General Practice Nurses in Motivation Support in Type 2 Diabetes Care: A Cluster-Randomised Trial

  2014cites this paper
• Update on lessons learned from glycemia control studies

  2014cites this paper
• The selective interaction of lixisenatide leads to an increase in intracellular cAMP and stimulates glucose‑dependent insulin secretion from pancreatic b‑cells, simultaneously decreasing glucagon secretion from a‑cells. Lixisenatide slows gastric emptying, thus improving postprandial glucose control

  2014cites this paper
• Effect of telehealth on glycaemic control: analysis of patients with type 2 diabetes in the Whole Systems Demonstrator cluster randomised trial

  2014cites this paper
• Achieving HbA1c targets in clinical trials and in the real world: a systematic review and meta-analysis

  2014cites this paper
• DIABETIC STUDIES The Review of The HbA 1 c and All-Cause Mortality Relationship in Patients with Type 2 Diabetes is J-Shaped : A Meta-Analysis of Observational Studies

  2014cites this paper
• A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative.

  2014cites this paper
• Studies of cardiovascular disease risk estimation: how, and whether, to account for the effect of drug treatment?

  2014cites this paper
• Mortality risk with sulphonylureas compared to metformin

  2014cites this paper
• Guideline for management of postmeal glucose in diabetes.

  2014cites this paper
• Lixisenatide: clinical profile and available evidence

  2014cites this paper
• Is glycemic control a quinidine‐like intervention? 控制血糖与使用奎尼丁治疗一样吗？

  2014cites this paper
• Diabetes: complications and the economic burden

  2014cites this paper
• A Review of Cardiovascular Outcomes in the Treatment of People with Type 2 Diabetes

  2014cites this paper
• Does Glycemic Control Reduce Cardiovascular Complications

  2014cites this paper
• Vom HbA1c zum Gesamtrisiko

  2014cites this paper
• Risk of Cardiovascular Disease among Diabetic Patients in Manipur, Northeast India

  2014cites this paper
• The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies.

  2014cites this paper
• Cardiovascular disease in diabetes mellitus: risk factors and medical therapy.

  2014cites this paper